These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27603498)

  • 1. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
    Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
    J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
    Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
    HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of costs associated with adverse events in patients with cancer.
    Wong W; Yim YM; Kim A; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A
    PLoS One; 2018; 13(4):e0196007. PubMed ID: 29652926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
    Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
    J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
    Pettigrew M; Kavan P; Surprenant L; Lim HJ
    J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden associated with adverse events in patients with metastatic melanoma.
    Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
    J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.
    Burudpakdee C; Zhao Z; Munakata J; Gao S; Trochlil K; Barber B
    J Med Econ; 2012; 15(2):371-7. PubMed ID: 22181051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA.
    Grivas P; DerSarkissian M; Shenolikar R; Laliberté F; Doleh Y; Duh MS
    Future Oncol; 2019 Nov; 15(33):3809-3818. PubMed ID: 31596144
    [No Abstract]   [Full Text] [Related]  

  • 20. Service setting impact on costs for bevacizumab-treated oncology patients.
    Engel-Nitz NM; Yu EB; Becker LK; Small A
    Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.